eltrombopag olamine (SB-497115-GR)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopaenic, Idiopathic

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Trial Timeline

Jun 1, 2006 โ†’ Jul 1, 2015

About eltrombopag olamine (SB-497115-GR)

eltrombopag olamine (SB-497115-GR) is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT00351468. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00351468Phase 3Completed